LYT-200

PureTech's LYT-200, an anti-galectin-9 monoclonal antibody, received FDA Fast Track designation for AML treatment, highlighting its potential across various treatment lines. Currently in Phase 1/2 trials for AML/MDS and head and neck cancers, LYT-200 shows promise in directly killing cancer cells and reactivating the immune system.

PureTech Health's KarXT, now marketed as Cobenfy, receives FDA approval for treating schizophrenia in adults, triggering $29m in payments from Royalty Pharma and Karuna Therapeutics. Cobenfy, developed by combining xanomeline with trospium chloride, aims to address tolerability issues in neuropsychiatric treatments. PureTech anticipates 2% royalties on net annual sales exceeding $2bn, with Cobenfy's success generating $1.1bn for the company, enabling self-funding of its pipeline, including LYT-100 for idiopathic pulmonary fibrosis.

PureTech Health announced FDA approval of KarXT for schizophrenia, triggering $29 million in milestone payments from Royalty Pharma and Karuna Therapeutics, acquired by Bristol Myers Squibb in 2024. KarXT will be marketed as Cobenfy, the first new drug mechanism for schizophrenia in over 50 years.